Fat embolism syndrome

Jump to navigation Jump to search
Fat embolism syndrome
ICD-10 O88.8, T79.1
ICD-9 673.8
DiseasesDB 4766
MeSH C14.907.355.350.454

Fat embolism syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fat embolism syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fat embolism syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fat embolism syndrome

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fat embolism syndrome

CDC on Fat embolism syndrome

Fat embolism syndrome in the news

Blogs on Fat embolism syndrome

Directions to Hospitals Treating Fat embolism syndrome

Risk calculators and risk factors for Fat embolism syndrome

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Epidemiology and Demographics

Pathophysiology

The pathogenesis of FES is not completely defined. It is thought to be caused by blockage of vessels from systemic embolization of fat globules. Echocardiographic reports have demonstrated echogenic material passing through the right atrium followed by increased pulmonary pressures and right heart pressures and subsequent paradoxical embolization of this material through a patent foramen ovale (PFO).

The fat induces a toxic, inflammatory reaction. This inflammatory reaction is thought to be related to the production of free fatty acids. Studies have shown that neutral fatty acids are not toxic , however, they are hydrolyzed over many hours to substances proven to cause ARDS in animal models. Not surprisingly, C-reactive protein is usually elevated in these patients. Levels of lipoprotein lipase, and free fatty acids (FFA) are noted in animal models.

Natural History

The syndrome typically occurs 12-24 hrs after the inciting event. It can occur as early as 12 hrs and as late as 2 weeks. Patients are often dyspneic, tachypneic and hypoxic. 50% of patients with FES require mechanical ventilation and progression to adult respiratory distress syndrome (ARDS) may develop.

The majority of patients develop neurologic abnormalities, usually after the development of respiratory distress. The usualy demonstrate an acute confusional state that may progress to coma. In most cases, if the patient survives, the neurologic abnormalities are transient.

The petichial rash is the last finding to develop. It occurs in only 30-50% of patients with FES. It is most often found on the head, neck, anterior thorax, subconjunctiva and axilla. It usually resolves in 5-7 days.

Scotoma, fever, lipiduria, disseminated intravascular coagulation (DIC) and cardiogenic shock are seen.

Diagnosis

FES is a clinical diagnosis. Chest X-rays are normal in the majority. Some may have evidence of consolidation, edema or hemmorhage, usually in the periphery. Pulmonary ventilation/perfusion scans (V/Q scans) demonstrate multiple subsegmental perfusion defects.

The recovery of fat from pulmonary artery (PA) catheter wedged blood, sputum and urine is nonspecific. One study found fat in 50% of sera from patients with long bone fractures who had no evidence of FES. Bronchoscopy and bronchoalveolar lavage (BAL) seem to be more specific by demonstrating fat droplets in alveolar macrophages.

Chest X Ray

Acute Respiratory Distress Syndrome (ARDS)


Echocardiography

Echocardiographic reports have demonstrated echogenic material passing through the right atrium followed by increased pulmonary pressures and right heart pressures and subsequent paradoxical embolization of this material through a patent foramen ovale (PFO).

Other Diagnostic Studies

Treatment

Mortality occurs in 5-15% of patients. Early immobilization of fractures and operative rather than conservative management decrease the risk of FES. Some studies have shown a benefit in steroid prophylaxis for patients at high risk for FES (closed pelvic fracture), while others have not. There is no benefit to steroids after FES has developed.

References

[1]

Acknowledgements

Source of Initial Content: Morning report notes prepared by Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] and Dr. Duane Pinto

External links

Template:Consequences of external causes

Template:WikiDoc Sources

  1. Gerald L. Weinhouse. Fat Embolism Syndrome.